[HTML][HTML] Efficacy of crizotinib among different types of ROS1 fusion partners in patients with ROS1-rearranged non–small cell lung cancer
Z Li, L Shen, D Ding, J Huang, J Zhang, Z Chen… - Journal of Thoracic …, 2018 - Elsevier
Introduction ROS1 rearrangement–positive NSCLC can be treated effectively with an
anaplastic lymphoma kinase/ROS1/mesenchymal-epithelial transition factor inhibitor such …
anaplastic lymphoma kinase/ROS1/mesenchymal-epithelial transition factor inhibitor such …
[HTML][HTML] Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non–Small Cell Lung Cancer
Z Li, L Shen, D Ding, J Huang, J Zhang, Z Chen… - Journal of Thoracic …, 2018 - jto.org
Introduction ROS1 rearrangement–positive NSCLC can be treated effectively with an
anaplastic lymphoma kinase/ROS1/mesenchymal-epithelial transition factor inhibitor such …
anaplastic lymphoma kinase/ROS1/mesenchymal-epithelial transition factor inhibitor such …
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Z Li, L Shen, D Ding, J Huang, J Zhang… - Journal of Thoracic …, 2018 - europepmc.org
Methods We reviewed clinicopathological data of patients with ROS1 rearrangement who
received crizotinib therapy at our institution between April 2014 and December 2016. ROS1 …
received crizotinib therapy at our institution between April 2014 and December 2016. ROS1 …
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer
Z Li, L Shen, D Ding, J Huang… - Journal of thoracic …, 2018 - pubmed.ncbi.nlm.nih.gov
Introduction ROS1 rearrangement-positive NSCLC can be treated effectively with an
anaplastic lymphoma kinase/ROS1/mesenchymal-epithelial transition factor inhibitor such …
anaplastic lymphoma kinase/ROS1/mesenchymal-epithelial transition factor inhibitor such …